02:08 , Jul 26, 2017 |  BC Extra  |  Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Paliperidone palmitate: Phase III final data

In January, FDA accepted and granted Priority Review to an NDA for the 3-month formulation of Invega Sustenna to treat schizophrenia in adults. The PDUFA date is May 18. Johnson & Johnson markets a once-monthly...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

DSP-1053: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-1053, which was in Phase I testing to treat MDD. The company said the compound did not...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Invega Sustenna paliperidone palmitate: Phase III data

A double-blind, international Phase III trial in 509 patients with schizophrenia was stopped early on the recommendation of an independent DMC after an interim analysis showed that a 3-month formulation of intramuscular Invega Sustenna met...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

Xeplion paliperidone palmitate: Phase III data

The open-label, international Phase III PROSIPAL trial in 715 patients with recently-diagnosed schizophrenia showed that once-monthly intramuscular injections with Xeplion for 2 years met the primary endpoint of increasing time to relapse event compared to...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

Zyprexa olanzapine: Phase III data

A double-blind Phase III trial in 80 cancer patients receiving highly emetogenic chemotherapy showed that a significantly greater proportion of patients receiving once-daily 10 mg oral Zyprexa for 3 days experienced no emesis during the...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

Invega Sustenna: Phase III data

In a 13-week, double-blind, placebo-controlled Phase III trial in 1,220 patients, once-monthly Invega Sustenna met the primary endpoint of non-inferiority to biweekly Risperdal Consta risperidone in decrease from baseline in PANSS total score (18.6 vs....
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Invega paliperidone ER: Phase IIIb data

Invega also resulted in significantly less weight gain vs. Zyprexa (p<0.0001). Serious treatment-emergent adverse events were reported in 5.7% of patients receiving Invega and in 7.3% of patients receiving Zyprexa. Data were presented at the...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

Seroquel quetiapine: Post-marketing study data

Data from the post-marketing SATIETY trial in 338 patients ages 4-19 showed that first-time use of 4 second-generation antipsychotic drugs - olanzapine, quetiapine, risperidone and aripiprazole - was associated with significant weight gain from baseline...
07:00 , Jul 20, 2009 |  BC Week In Review  |  Clinical News

Seroquel quetiapine: Post-marketing study data

A study of 66,881 schizophrenics in Finnish registries showed that patients who took antipsychotics for 7-11 years had a 19% lower risk of death compared with patients taking no antipsychotics (p<0.0001). The risk of death...